Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study

Rabe, 2007, Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary, Am J Respir Crit Care Med, 176, 532, 10.1164/rccm.200703-456SO Barnes, 2017, GOLD 2017: a new report, Chest, 151, 245, 10.1016/j.chest.2016.11.042 Izquierdo, 2010, Misdiagnosis of patients receiving inhaled therapies in primary care, Int J Chron Obstruct Pulmon Dis, 5, 241, 10.2147/COPD.S11123 Suissa, 2017, Long-acting bronchodilator initiation in COPD and the risk of adverse cardio-pulmonary events: A population-based comparative safety study, Chest, 151, 60, 10.1016/j.chest.2016.08.001 Postma, 2009, Inhaled corticosteroids in COPD: a case in favour, Eur Respir J, 34, 10, 10.1183/09031936.00022809 Suissa, 2009, Inhaled corticosteroids in COPD: the case against, Eur Respir J, 34, 13, 10.1183/09031936.00190908 Ernst, 2015, Inhaled corticosteroids in COPD: the clinical evidence, Eur Respir J, 45, 525, 10.1183/09031936.00128914 Vogelmeier, 2011, Tiotropium versus salmeterol for the prevention of exacerbations of COPD, N Engl J Med, 364, 1093, 10.1056/NEJMoa1008378 Wedzicha, 2008, The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide, Am J Respir Crit Care Med, 177, 19, 10.1164/rccm.200707-973OC Bafadhel, 2017, Eosinophils in COPD: just another biomarker?, Lancet Respir Med, 5, 747, 10.1016/S2213-2600(17)30217-5 Pascoe, 2015, Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials, Lancet Respir Med, 3, 435, 10.1016/S2213-2600(15)00106-X Pavord, 2016, Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis, Lancet Respir Med, 4, 731, 10.1016/S2213-2600(16)30148-5 Watz, 2016, Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial, Lancet Respir Med, 4, 390, 10.1016/S2213-2600(16)00100-4 Brusselle, 2015, Targeted therapy with inhaled corticosteroids in COPD according to blood eosinophil counts, Lancet Respir Med, 3, 416, 10.1016/S2213-2600(15)00145-9 Iyer, 2016, Serum eosinophils as a COPD biomarker: ready for prime time?, Lancet Respir Med, 4, 341, 10.1016/S2213-2600(16)30040-6 Suissa, 2017, Precision medicine urgency: the case of inhaled corticosteroids in COPD, Chest, 152, 227, 10.1016/j.chest.2017.05.020 Barnes, 2016, Asthma–COPD overlap, Chest, 149, 7, 10.1016/j.chest.2015.08.017 Miravitlles, 2017, Diagnosis of asthma–COPD overlap: the five commandments, Eur Respir J, 49, 1700506, 10.1183/13993003.00506-2017 Jick, 2003, Validity of the general practice research database, Pharmacotherapy, 23, 686, 10.1592/phco.23.5.686.32205 Herrett, 2010, Validation and validity of diagnoses in the General Practice Research Database: a systematic review, Br J Clin Pharmacol, 69, 4, 10.1111/j.1365-2125.2009.03537.x Herrett, 2015, Data resource profile: Clinical Practice Research Datalink (CPRD), Int J Epidemiol, 44, 827, 10.1093/ije/dyv098 Quint, 2014, Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD), BMJ Open, 4, e005540, 10.1136/bmjopen-2014-005540 Rothnie, 2016, Validation of the recording of acute exacerbations of COPD in UK primary care electronic healthcare records, PLoS One, 11, e0151357, 10.1371/journal.pone.0151357 Millett, 2016, Improved incidence estimates from linked vs. stand-alone electronic health records, J Clin Epidemiol, 75, 66, 10.1016/j.jclinepi.2016.01.005 Schneeweiss, 2009, High-dimensional propensity score adjustment in studies of treatment effects using health care claims data, Epidemiology, 20, 512, 10.1097/EDE.0b013e3181a663cc Oshagbemi, 2017, Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts, Am J Respir Crit Care Med, 195, 1402, 10.1164/rccm.201701-0009LE Hospers, 2000, Eosinophilia is associated with increased all-cause mortality after a follow-up of 30 years in a general population sample, Epidemiology, 11, 261, 10.1097/00001648-200005000-00006 Vedel-Krogh, 2016, Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen general population study, Am J Respir Crit Care Med, 193, 965, 10.1164/rccm.201509-1869OC Couillard, 2017, Eosinophils in COPD exacerbations are associated with increased readmissions, Chest, 151, 366, 10.1016/j.chest.2016.10.003 Pavord, 2016, Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD, Thorax, 71, 118, 10.1136/thoraxjnl-2015-207021 Roche, 2017, Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial, Am J Respir Crit Care Med, 195, 1189, 10.1164/rccm.201701-0193OC Barnes, 2016, Blood eosinophils as a marker of response to inhaled corticosteroids in COPD, Eur Respir J, 47, 1374, 10.1183/13993003.01370-2015 Vestbo, 2016, Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice, N Engl J Med, 375, 1253, 10.1056/NEJMoa1608033 Suissa, 2008, Methodological issues in therapeutic trials of COPD, Eur Respir J, 31, 927, 10.1183/09031936.00098307 Vestbo, 2011, Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study, Clin Respir J, 5, 44, 10.1111/j.1752-699X.2010.00198.x Suissa, 2017, Run-in bias in randomised trials: the case of COPD medications, Eur Respir J, 49, 1700361, 10.1183/13993003.00361-2017